The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Incyte; Mercer; Novartis; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Novartis
 
Consulting or Advisory Role - Bayer; Eisai; Genzyme; Ipsen
Research Funding - Bayer (Inst); Eisai (Inst); Genzyme (Inst); Ipsen (Inst)
A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209.
 
Martin Schlumberger
No Relationships to Disclose
 
Kate Newbold
No Relationships to Disclose
 
Baktiar Hasan
No Relationships to Disclose
 
Sandrine Marreaud
No Relationships to Disclose
 
Samson Assele
No Relationships to Disclose
 
Lisa F. Licitra
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group; Eisai; Merck Serono; MSD; Novartis; Roche; SOBI
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Debiopharm Group; Merck Serono; SOBI
 
Patrick Schoffski
Consulting or Advisory Role - Blueprint Medicines (Inst); Eisai (Inst); Ellipses Pharma (Inst); Epizyme (Inst); Ipsen (Inst); Lilly (Inst); Loxo (Inst); Piqur (Inst); Plexxikon (Inst)
Research Funding - Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); CoBioRes NV (Inst); Eisai (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); Plexxikon (Inst)
 
Sophie Leboulleux
No Relationships to Disclose
 
Laura Locati
Consulting or Advisory Role - Eisai; Ipsen
Speakers' Bureau - Eisai
 
Yann Godbert
No Relationships to Disclose
 
Vincent Rohmer
No Relationships to Disclose
 
Barbara Jarzab
No Relationships to Disclose
 
Salvatore Domenico
No Relationships to Disclose
 
Oliver Edgar Bechter
No Relationships to Disclose
 
Sylvie Zanetta
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Jaume Capdevila
No Relationships to Disclose
 
Ellen Kapiteijn
No Relationships to Disclose
 
Lars Bastholt
No Relationships to Disclose